Resultados de la búsqueda 31-40 of 12681 for Two-phase

  1. Hematología - Ensayos clínicos - Mayo Clinic

    Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in ...

  2. Hematología - Ensayos clínicos - Mayo Clinic

    Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in ...

  3. Hematología - Ensayos clínicos - Mayo Clinic

    Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The primary objective of Part 1 of this study is to define the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-220 in ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The primary objective of Part 1 of this study is to define the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-220 in ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The primary objective of Part 1 of this study is to define the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-220 in ...

  7. Hematología - Ensayos clínicos - Mayo Clinic

    Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Randomized Phase II/III Trial of Adjuvant ... A Study to Compare Two Surgical Procedures in Women With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer.

  9. Hematología - Ensayos clínicos - Mayo Clinic

    ... phase II dose (RP2D of APG2575 in combination ... Patients will be randomized 1:1 into the two arms. ... 2-6: 500 mg/m2). Patients randomized to B+R will ...

  10. Clínica de las mamas - Ensayos clínicos - Mayo Clinic

    Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer. Rochester, Minn. This ...